Clinical Research at the Chase Family Movement Disorders Center

The Chase Family Movement Disorders Center offers opportunities for active participation in cutting edge research in the field of Parkinson disease, Dystonia, Huntington disease, Essential Tremor and other Movement Disorders through clinical trials.

These studies are conducted in collaboration with other movement disorders specialists throughout North America and Europe. We have several ongoing clinical research studies as noted below, and all eligible patients have the option to participate in any of these clinical trials.

We are also involved in mentoring students, providers and physicians-in-training who will serve the community in the future as neurologists, researchers, or primary care clinicians.

Clinical Trials

The Chase Family Movement Disorders Center continues to seek new ways to manage symptoms, slow the progression or observe trends in neurodegenerative disorders through clinical trials, in collaboration with other movement disorders specialists and research consortia.

Our Vernon location is currently participating in the following clinical trials. For more information on how to become an integral part of research, please contact our Clinical Research Nurse and Study Coordinator, Rachael Geoffrion, RN at 860.870.6385 x65503 or at Rachael.Geoffrion@hhchealth.org.

• Protocol No: ND0612-317 (NeuroDerm BouNDless - currently enrolling)
  A phase 3 multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations.

• Protocol No: ADX48621-301 (Addex – currently enrolling)
  A phase 2b/3, randomized, double-blind, placebo-controlled, parallel-group multicenter study to evaluate the safety and efficacy of dipraglurant (ADX48621) for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy with or without concomitant dopaminergic medications.

• Protocol No: HHC-2021-0019 (Naboso - currently enrolling)
  A Hartford HealthCare investigator-initiated randomized double-blind placebo-controlled study to evaluate the effectiveness of textured insoles in decreasing the rate of falls and near falls and improving balance and gait measures among patients with Parkinson disease.

Our Cheshire location is currently participating in the following clinical trials. For more information on how to become an integral part of research, please contact our Clinical Research Coordinator at CFMDC Cheshire, Penelope Ross, at 860.870.6385 or at Penelope.ross@hhchealth.org.

• Protocol No.: Neurocrine Biosciences, Inc. NBI-OPC-PD4006 (currently enrolling)
  A prospective, open-label, single-arm, multicenter observational study designed to describe the outcomes observed with use of ONGENTYS as a adjunctive treatment to levodopa/carbidopa in treating Parkinson’s disease patients.